Evidence map›Paper›PMID 41721751›Full record

ArticleCPT: pharmacometrics & systems pharmacology2026

Open Systems Pharmacology Community Conference (OSP-CC) Proceedings 2025.

Henrik Cordes, Pieter Annaert, Pavel Balazki, Salih Benamara, Rodolfo Hernandes Bonan, Andrew Butler, Marylore Chenel, Yunhai Cui, André Dallmann, Wilhelmus E A de Witte and 26 more

Abstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in CPT: pharmacometrics & systems pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Henrik CordesResearch Pharmacometrics, Sanofi R&D, Frankfurt am Main, Germany.ORCID https://orcid.org/0000-0002-0654-3386
Pieter AnnaertDrug Delivery and Disposition, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.ORCID https://orcid.org/0000-0003-3525-7351
Pavel BalazkiESQlabs GmbH, Saterland, Germany.ORCID https://orcid.org/0009-0006-3197-0984
Salih BenamaraDiscovery-Pharmacometrics, Sanofi R&D, Paris, France.
Rodolfo Hernandes BonanBioNotus CommV, Niel, Belgium.ORCID https://orcid.org/0000-0001-5944-2602
Andrew ButlerMedicines and Healthcare Products Regulatory Agency, London, UK.ORCID https://orcid.org/0000-0003-4362-940X
Marylore ChenelPharmetheus AB, Uppsala, Sweden.ORCID https://orcid.org/0000-0001-7397-4007
Yunhai CuiBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.ORCID https://orcid.org/0000-0003-4969-072X
André DallmannBayer HealthCare SAS, Lille, France.ORCID https://orcid.org/0000-0003-1108-5719
Wilhelmus E A de WitteESQlabs GmbH, Saterland, Germany.
Cleo DemeesterDrug Delivery and Disposition, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.ORCID https://orcid.org/0009-0001-1349-1764
Denise FeickResearch Pharmacometrics, Sanofi R&D, Frankfurt am Main, Germany.ORCID https://orcid.org/0000-0002-4047-402X
Florence GattaccecaComputational Pharmacology and Clinical Oncology Department, Inria Sophia Antipolis - Méditerranée, Biot, France.ORCID https://orcid.org/0000-0002-4944-8063
René GeciESQlabs GmbH, Saterland, Germany.ORCID https://orcid.org/0000-0002-1219-6835
Grégori GerebtzoffBiomedical Research, Novartis, Basel, Switzerland.ORCID https://orcid.org/0000-0002-7580-4463
Andrea GruberModeling & Simulation, Research & Development, Pharmaceuticals, Bayer AG, Berlin, Germany.ORCID https://orcid.org/0000-0001-8298-5090
Mariana GuimarãesESQlabs GmbH, Saterland, Germany.ORCID https://orcid.org/0009-0003-2896-8822
Abdullah HamadehSchool of Pharmacy, University of Waterloo, Kitchener, Ontario, Canada.ORCID https://orcid.org/0000-0002-9419-1797
Nina HankeBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany.ORCID https://orcid.org/0000-0001-6166-8838
Manuel IbarraDepartment of Pharmaceutical Sciences, Faculty of Chemistry, Universidad de la República, Montevideo, Uruguay.ORCID https://orcid.org/0000-0002-0484-6367
Ibrahim InceBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.
Tobias KanacherPharmetheus AB, Uppsala, Sweden.ORCID https://orcid.org/0009-0002-0625-6616
Lars KuepferInstitute for Systems Medicine With Focus on Organ Interaction, University Hospital RWTH Aachen, Aachen, Germany.ORCID https://orcid.org/0000-0002-8741-7786
Felix MilESQlabs GmbH, Saterland, Germany.
Ghazal MontaseriBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.
Nina NauwelaertsESQlabs GmbH, Saterland, Germany.ORCID https://orcid.org/0000-0001-5301-6813
Susana ProencaESQlabs GmbH, Saterland, Germany.ORCID https://orcid.org/0000-0003-1544-4686
Stephan SchallerESQlabs GmbH, Saterland, Germany.ORCID https://orcid.org/0000-0003-1046-7651
Jan Frederik SchlenderBiomedical Research, Novartis, Basel, Switzerland.ORCID https://orcid.org/0009-0003-9079-5205
Annika R P SchneiderModel-Informed Drug Development, Research & Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.ORCID https://orcid.org/0000-0003-1377-7102
Erik SjögrenPharmetheus AB, Uppsala, Sweden.ORCID https://orcid.org/0000-0003-4318-6039
Juri SolodenkoModel-Informed Drug Development, Research & Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.ORCID https://orcid.org/0000-0001-6922-588X
Alexander StaabBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.
Paul VrenkenPharmetheus AB, Uppsala, Sweden.ORCID https://orcid.org/0009-0007-2543-201X
Carla TroisiESQlabs GmbH, Saterland, Germany.ORCID https://orcid.org/0009-0007-5617-0331
Donato TeutonicoDiscovery-Pharmacometrics, Sanofi R&D, Paris, France.ORCID https://orcid.org/0000-0003-4931-410X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Developed at Bayer Technology Services, PK-Sim and MoBi transitioned into the Open Systems Pharmacology (OSP) Suite, released as free open-source software in 2017. An active community with stakeholders from academia, industries, and regulators contributes to the continuous improvement of open-source model-informed drug development (MIDD). This perspective summarizes the latest advancements presented at the second OSP Community Conference (OSP-CC) hosted from 29 to 30th of September 2025 at Sanofi Paris, that gathered over 100 attendees from more than 40 institutions.

Indexed as

Drug DevelopmentSystems BiologySoftware

Identifiers

PMID41721751
PMCPMC12962394

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.